| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 3
Formulation and optimization: Liquisolid of domperidone for solubility enhancement
1 Guru Jambheshwar University of Science and Technology, Departmental of Pharmaceutical Sciences, Hisar, 125001, India2 Om Sterling Global University, School of Pharmaceutical Sciences, Hisar, 125001, India
DOI : 10.23893/1307-2080.APS6234 Viewed : 5035 - Downloaded : 2564 In the present study, liquisolid formulations of domperidone were prepared using Tween 80, microcrystalline cellulose, Aerosil 200 as solvent, carrier, and coating material, respectively. 2-factors, 3-level central composite experimental design was employed to examine the effect of independent variables (excipient ratio and load factor) on dependent variables (solubility and drug content). Differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), X-ray powder diffraction (XRD) and scanning electron microscopy (SEM) studies were utilized to characterize the optimized formulation. The results of solubility studies of different batches of liquisolid formulations revealed an improvement in solubility ranging from 17.02-58.10 µg/mL as compared to pure drug domperidone (7.47 µg/mL). The in-vitro dissolution profile of optimized batch of liquisolid formulation depicted higher rate of drug release (93.63%) when compared with conventional marketed tablets (Dompy®, 81.98%) following non fickian diffusion (n<0.5) as mechanism of drug release from the matrix. Keywords : liquisolid, domperidone, solubility enhancement, optimization